Please ensure Javascript is enabled for purposes of website accessibility

Why AMAG Pharmaceuticals Stock Is Skyrocketing Today

By Keith Speights – Updated Oct 1, 2020 at 5:35AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company is being gobbled up by another drugmaker.

What happened

Shares of AMAG Pharmaceuticals (AMAG) were skyrocketing 44.6% higher as of 11:10 a.m. EDT on Thursday. The huge jump began Thursday morning after Bloomberg reported that Covis Pharma, a drugmaker backed by Apollo Global Management (APO), is in talks to acquire AMAG. Covis confirmed this report later in the day by announcing that it plans to buy AMAG for around $647 million.

So what

Covis' offer reflects a 46% premium above AMAG's closing price on Wednesday. So why hasn't the biotech stock moved even higher today? Investors realize that there's always a chance that the deal won't close for some reason.

Two jigsaw puzzle pieces close to connecting

Image source: Getty Images.

It's not surprising in the least that AMAG was in the market to be taken over. Earlier this year, the company announced that it was performing a strategic review of its products and business strategy. That review led to AMAG selling its women's health products business, a move that could have increased the company's attractiveness to potential acquirers.

Covis CEO Michael Porter said that AMAG's products are "strong strategic complements" to Covis' lineup. He added that the acquisition would "unlock value for all of our stakeholders."

Now what

The deal has already been unanimously approved by both AMAG's and Covis' boards of directors. Next steps include regulatory approval and the tender of AMAG's shares. All of AMAG's board members and executives have agreed to tender their shares to support the acquisition. Assuming there are no roadblocks, the transaction is expected to close in November.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.